<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077034</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNO-01</org_study_id>
    <nct_id>NCT04077034</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Formula DE111® on Immune System in Preschool Children</brief_title>
  <acronym>IMMUNOFORM</acronym>
  <official_title>A Randomized, Parallel, Double Blind, Placebo Controlled Clinical Study Evaluating the Effect of Probiotic Formula on Immune System in Preschool Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deerland Enzymes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vizera d.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deerland Enzymes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy preschool children will be recruited, gastrointestinal infection and respiratory
      infection symptoms will be followed during the 8-week treatment and 4-week follow-up period,
      to evaluate the effect of the used probiotic formula on immune system in comparison to the
      group using placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Actual">August 12, 2019</completion_date>
  <primary_completion_date type="Actual">August 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of gastrointestinal and/or respiratory infections for experimental group compared to control group</measure>
    <time_frame>12-week study period (consisting of 8-week treatment plus 4-week follow-up)</time_frame>
    <description>Number of participants with at least one occurrence of gastrointestinal and/or respiratory infections during 12-week study period in the experimental group compared to control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of adverse events occuring in the experimental group compared to control group</measure>
    <time_frame>12-week study period (consisting of 8-week treatment plus 4-week follow-up)</time_frame>
    <description>Number of participants with treatment related adverse events during 12-week study period for both, experimental and control group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Immune System Support</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic DE111®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Formula Bacillus subtilis DE111®</intervention_name>
    <description>Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Placebo comparator, once a day for 8 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent by at least one parent or legal guardian

          -  children aged 2 to 6 years

          -  attending or about to start attending day-care

        Exclusion Criteria:

          -  body weight at birth &lt;2500g

          -  gestational age &lt;37 weeks

          -  severe chronic illness

          -  regular use of medication

          -  immunodeficiency

          -  parent or legal guardian not able to understand and comply with requirements of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilijana Kocijancic Besednjak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Center Nova Gorica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health center Laško</name>
      <address>
        <city>Laško</city>
        <zip>3270</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrija Krebs</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrinja d.o.o.</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zasebna otroska in solska ambulanta</name>
      <address>
        <city>Maribor</city>
        <zip>2230</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center Nova Gorica</name>
      <address>
        <city>Šempeter Pri Gorici</city>
        <zip>5290</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

